By the Proco Research Team
"Omega-3 is good for your heart" is one of the least controversial claims in supplements — and, looked at closely, one of the more contested ones in the actual trial literature. Two major, recent, high-quality reviews looked at the same broad evidence base and landed in genuinely different places. The reason isn't sloppy science on either side. It's that the underlying randomized trials themselves disagree, sometimes sharply, and the two reviews simply weighted that disagreement differently. Here's the whole picture, honestly.
The skeptical case
A 2020 Cochrane review — generally considered the most rigorous standard in evidence synthesis — pooled 79 randomized trials in 112,059 participants.1 Its conclusion: long-chain omega-3 supplements provide little if any benefit on most outcomes, with high-certainty evidence of no meaningful effect on all-cause mortality (8.8% vs 9.0% in controls) and probably minimal difference to cardiovascular events, coronary heart disease, or stroke risk. It did lower triglycerides — but also lowered protective HDL cholesterol alongside it.
The more favorable case
A 2021 meta-analysis in the Journal of the American Heart Association pooled 13 randomized trials in 127,477 participants and reached a more positive conclusion: real, if modest, risk reductions for myocardial infarction (8% lower), CHD death (8% lower), and cardiovascular death (7% lower) — though no benefit for stroke.2 Critically, it found a dose-response relationship: benefit scaled with dose, with each additional 1,000mg/day associated with a further 9% lower MI risk in the pooled data.
That dose-response finding is the thread worth pulling. A handful of large individual trials sit inside these pooled numbers, and they don't just differ in magnitude — they point in different directions entirely. To understand why the two reviews disagree, it helps to look at the three trials that did the most to shape them.
Three trials, three different answers
REDUCE-IT, VITAL, and STRENGTH are the three largest, most-discussed cardiovascular outcome trials of the last decade, and they're the reason omega-3's reputation is so split. All three were large, well-run, randomized, and published in major journals — and they reached three different conclusions.
| Trial | Formulation & dose | Comparator & result |
|---|---|---|
| REDUCE-IT (2019) | Purified EPA (icosapent ethyl), 4,000mg/day | Mineral oil placebo — 25% relative risk reduction in major CV events3 |
| VITAL (2019) | Mixed EPA+DHA, ~840mg/day, healthy adults | Olive oil placebo — no significant reduction in major CV events (HR 0.92)4 |
| STRENGTH (2020) | Mixed EPA+DHA (carboxylic acid), 4,000mg/day | Corn oil placebo — no benefit (12.0% vs 12.2%), stopped early for futility5 |
Only REDUCE-IT was positive, and it differs from the other two in two ways at once: it used a purified, EPA-only formulation rather than a mixed EPA/DHA one, and it used a mineral oil placebo rather than a vegetable oil. Which of those two differences actually explains the result is a real, unresolved argument in cardiology — and it matters, because Proco's Omega-3 (and most fish oil supplements) are mixed EPA+DHA formulations, not purified EPA at prescription doses.
The placebo problem
STRENGTH's trial chair, Steven Nissen, and colleagues published an analysis directly questioning whether REDUCE-IT's result reflected the drug doing good or the placebo doing harm. Their argument, published in Circulation: mineral oil is inert and unabsorbed, but in REDUCE-IT's placebo arm it was associated with a 10.2% rise in LDL cholesterol and a 32% rise in high-sensitivity C-reactive protein — changes that didn't occur with the corn oil placebo used in STRENGTH.6 If the placebo group's own biomarkers were quietly getting worse, some of the apparent 25% benefit could be the comparator underperforming rather than the drug overperforming.
It isn't a settled question. A separate analysis, commissioned to address the same critique and published in European Heart Journal Supplements, examined mineral oil's safety record across trials and reported that its effects on lipids, inflammatory markers, and drug absorption were inconsistent and generally not statistically or clinically meaningful.7 REDUCE-IT's own investigators counter that the difference is the drug, not the placebo — arguing that purified EPA has membrane-stabilizing effects that a mixed EPA/DHA formulation, like the one used in STRENGTH, may partially cancel out. Both explanations remain live in the cardiology literature. Neither one changes the fact that the two trials that used ordinary fish-oil formulations closer to what's actually sold as a supplement — VITAL and STRENGTH — found no cardiovascular benefit.
The one trial that showed a large benefit used a prescription-only, purified-EPA drug at 4,000mg/day against a placebo whose own chemistry is still being argued about — not a maintenance-dose fish oil supplement.
Why they disagree — and what it means for a standard dose
Some of the gap between the two pooled reviews comes down to exactly this: how much weight each one gave to REDUCE-IT's very high-dose, prescription EPA result, which pulled the JAHA meta-analysis's dose-response curve upward.2 That's a meaningfully different product and dose than a standard over-the-counter maintenance serving — icosapent ethyl is a prescription drug, taken at more than 13 times the EPA content of a typical daily fish oil capsule. Proco Omega-3 is dosed at 180mg EPA + 120mg DHA — a studied, disclosed maintenance dose aimed at closing a dietary gap, and nowhere near the dose or formulation driving REDUCE-IT's positive signal.
Bottom line
The honest position sits between the two headlines, and inside the trial-level disagreement that produced them: omega-3's cardiovascular case is real but modest at typical supplement doses, essentially absent for stroke, largely absent in the two largest trials that used formulations closest to an ordinary supplement, and the strongest positive evidence comes from a purified prescription drug at a dose most people will never take — tested against a placebo whose own effects are still being debated. We'd rather say that plainly than lean on "good for your heart" as an unqualified claim the evidence doesn't fully support at the dose on our label.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, 2020. cochrane.org
- Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants. Journal of the American Heart Association, 2021. ahajournals.org
- Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine, 2019. nejm.org
- Manson JE, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL). New England Journal of Medicine, 2019. nejm.org
- Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH). JAMA, 2020. jamanetwork.com
- Nissen SE, et al. Summoning STRENGTH to Question the Placebo in REDUCE-IT. Circulation, 2021. ahajournals.org
- Olshansky B, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. European Heart Journal Supplements, 2020. academic.oup.com
Related reading: Omega-3 Dosage Guide: EPA, DHA, and What the Research Says and Omega-3 and Cognitive Function: EPA, DHA, and What Dose Actually Matters.
Proco Omega-3 delivers 180mg EPA + 120mg DHA per serving, third-party tested every batch. Shop Omega-3 →